Cue Biopharma (NASDAQ:CUE – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.
Analyst Recommendations
This is a summary of recent ratings and target prices for Cue Biopharma and Nurix Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cue Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Nurix Therapeutics has a consensus price target of $34.21, indicating a potential upside of 30.89%. Given Nurix Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Cue Biopharma.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cue Biopharma | $27.47 million | 7.25 | -$26.60 million | ($27.02) | -1.02 |
| Nurix Therapeutics | $83.98 million | 32.30 | -$264.46 million | ($3.45) | -7.58 |
Cue Biopharma has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Insider and Institutional Ownership
35.0% of Cue Biopharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Cue Biopharma and Nurix Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cue Biopharma | -435.83% | -620.06% | -291.15% |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
Summary
Nurix Therapeutics beats Cue Biopharma on 8 of the 14 factors compared between the two stocks.
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
